RBC Capital Markets disclosed Concordia Healthcare Corp (TSE:CXR), hiking its price target to $3.50 earlier today
- Updated: November 28, 2016
Indicating a possible downside of 0.00%, RBC Capital Markets increased the stock price target of Concordia Healthcare Corp (TSE:CXR) to $3.50
Previously on Monday November 21, 2016, RBC Capital Markets reported on Concordia Healthcare Corp (TSE:CXR) raised the target price from $0.00 to $3.50. At the time, this indicated a possible downside of -0.22%.
Just yesterday Concordia Healthcare Corp (TSE:CXR) traded -3.10% lower at $3.51. CXR’s 50-day average is $4.47 and its two hundred day average is $17.59. With the last close down -80.45% relative to the two hundred day average, compared with the S&P 500 Index which has decreased -0.03% over the same time. 120,466 shares of the stock were exchanged, down from an average trading volume of 1,086,090
See Chart Below
Concordia Healthcare Corp has a 52 week low of $2.27 and a 52 week high of $28.35 The company’s market cap is currently $0.
In addition to RBC Capital Markets reporting its target price, a total of 8 firms have reported on the stock. The consensus target price is $4.86 with 0 firms rating the stock a strong buy, 0 firms rating the stock a buy, 0 firms rating the stock a hold, 0 firms rating the stock a underperform, and finally 0 firms rating the stock a sell.
About Concordia Healthcare Corp (TSE:CXR)
Concordia International Corp, formerly Concordia Healthcare Corp, is a Canada-based pharmaceutical company. The Company, through subsidiaries, owns a portfolio of branded and generic prescription products. Its activities are divided into four segments: Concordia North America, includes sales of pharmaceutical products, such as Donnatal for the treatment of irritable bowel syndrome, Zonegran for the treatment of partial seizures in adults with epilepsy and Nilandron for the treatment of metastatic prostate cancer; Concordia International, includes a portfolio of branded and generic products that are sold to wholesalers, hospitals and pharmacies in over 100 countries, and focuses on acquisition, licensing and development of off-patent prescription medicines; Orphan Drugs, includes Photofrin, which is for the treatment of certain forms of rare cancer, and Corporate cost centre, includes centralized costs incurred by the Company.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.